PDS Biotechnology Corp. (PDSB)
1.09
-0.07
(-6.03%)
USD |
NASDAQ |
Oct 23, 12:48
PDS Biotechnology Enterprise Value : 63.64M for Oct. 22, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 22, 2026 | 63.64M |
| October 21, 2026 | 68.11M |
| October 20, 2026 | 52.48M |
| October 19, 2026 | 50.02M |
| October 16, 2026 | 61.96M |
| October 15, 2026 | 71.47M |
| October 14, 2026 | 77.62M |
| October 13, 2026 | 88.24M |
| October 12, 2026 | 83.77M |
| October 09, 2026 | 75.94M |
| October 08, 2026 | 55.81M |
| October 07, 2026 | 58.32M |
| October 06, 2026 | 57.21M |
| October 05, 2026 | 65.87M |
| October 02, 2026 | 40.62M |
| October 01, 2026 | 38.25M |
| September 30, 2026 | 40.75M |
| September 29, 2026 | 40.31M |
| September 28, 2026 | 41.60M |
| September 25, 2026 | 43.34M |
| September 24, 2026 | 43.51M |
| September 23, 2026 | 44.84M |
| September 22, 2026 | 49.66M |
| September 21, 2026 | 45.85M |
| September 18, 2026 | 43.81M |
| Date | Value |
|---|---|
| September 17, 2026 | 45.86M |
| September 16, 2026 | 54.16M |
| September 15, 2026 | 31.50M |
| September 14, 2026 | 21.09M |
| September 11, 2026 | 15.26M |
| September 10, 2026 | 16.40M |
| September 09, 2026 | 15.15M |
| September 08, 2026 | 15.54M |
| September 04, 2026 | 11.07M |
| September 03, 2026 | 11.07M |
| September 02, 2026 | 10.62M |
| September 01, 2026 | 10.18M |
| August 31, 2026 | 10.73M |
| August 28, 2026 | 10.56M |
| August 27, 2026 | 10.95M |
| August 26, 2026 | 11.25M |
| August 25, 2026 | 11.15M |
| August 24, 2026 | 10.89M |
| August 21, 2026 | 10.99M |
| August 20, 2026 | 10.45M |
| August 19, 2026 | 9.991M |
| August 18, 2026 | 10.40M |
| August 17, 2026 | 11.10M |
| August 14, 2026 | 11.66M |
| August 13, 2026 | 11.81M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.613B |
| Alnylam Pharmaceuticals, Inc. | 30.07B |
| Anika Therapeutics, Inc. | 269.09M |
| Savara, Inc. | 789.89M |
| Vericel Corp. | 2.131B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.751M |
| Total Expenses (Quarterly) | 9.751M |
| EPS Diluted (Quarterly) | -0.1752 |
| Earnings Yield | -58.74% |
| Normalized Earnings Yield | -58.74 |